[Skip to Navigation]
Comment & Response
January 26, 2022

Venous Thromboembolism in Chronic Inflammatory Skin Diseases—The Need to Consider Bullous Pemphigoid—Reply

Author Affiliations
  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 4Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC
  • 5Associate Editor, JAMA Dermatology
JAMA Dermatol. 2022;158(3):331-332. doi:10.1001/jamadermatol.2021.3828

In Reply We thank Marzano et al for their interest in our article1 and agree that understanding the background risk of venous thrombotic events (VTEs) in chronic inflammatory skin diseases (CISDs) is critical. The CISDs selected for this initial study were among the more common and currently have multiple clinical trials assessing Janus kinase (JAK) inhibitors, a target potentially associated with VTE risk, for these indications. Future studies are under way to investigate VTE risk in very rare CISDs that affect different patient populations, such as bullous pemphigoid. We agree there is differential risk between dermatologic conditions, and it is critical not to extrapolate the results from 1 set of patients to another.

Add or change institution